Search | Clinical Trials Finder

Conditions: Vaginitis Gardnerella
Interventions: Amoxicillin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • Winston-Salem, North Carolina

Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions: Artesunate vaginal insert, Placebo vaginal insert; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 25 Years to 100 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more

Conditions: HIV Infections, Cervix, Dysplasia
Interventions: Fluorouracil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 19
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 13 more

Conditions: Bacterial Vaginosis, Vaginal Microbiome, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginitis
Interventions: Menstrual Cup; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 15 Years to 35 Years · Female only
Enrollment: 408 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bacterial Vaginosis
Interventions: Low dose LACTIN-V applicator, Medium dose LACTIN-V applicator, High dose LACTIN-V applicator, Low dose Placebo applicator, Medium dose Placebo, High dose Placebo applicator; Biological · Other
Lead sponsor: Osel, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pelvic Organ Prolapse, Urinary Incontinence, Pelvic Floor Disorders, Gynecologic Disease, Post-Op Infection, Surgical Site Infection, Urinary Tract Infections
Interventions: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older · Female only
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Bacterial Vaginosis
Interventions: SYM-1219; Drug
Lead sponsor: Symbiomix Therapeutics; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 34 more

Conditions: Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions: Oral Encochleated Amphotericin B (CAMB), Fluconazole; Drug
Lead sponsor: Matinas BioPharma Nanotechnologies, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Bacterial Vaginosis, Candida Vaginitis
Interventions: cobas® BV/CV test, BD Max™ Vaginal Panel, Cepheid Xpert Xpress MVP, Hologic Aptima BV Assay; Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 738 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Lakewood, Colorado + 5 more

Conditions: Recurrent Urinary Tract Infection, Urinary Tract Infections, Cystitis Recurrent
Interventions: Vaginal estradiol tablets; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 55 Years to 100 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bacterial Vaginosis
Interventions: DARE-BV1clindamycin phosphate vaginal gel, 2%; Drug
Lead sponsor: Daré Bioscience, Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 10
States / cities: Tucson, Arizona • Denver, Colorado • Miami, Florida + 6 more

Conditions: Vaginitis Trichomonal or Due to Trichomonas
Interventions: MTZ 500 mg twice daily x 7 days, MTZ 2 g; Drug
Lead sponsor: Tulane University Health Sciences Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Birmingham, Alabama • New Orleans, Louisiana • Jackson, Mississippi

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Oteseconazole (VT-1161), Placebo; Drug
Lead sponsor: Mycovia Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Vulvovaginal Candidiasis
Interventions: Butoconazole Nitrate Vaginal Cream, Placebo, Gynazole 1 vaginal cream; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 611 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Genitourinary System; Disorder, Female, Burning Vagina, Dyspareunia, Irritation; Vagina, Menopause Related Conditions, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Tract Infections, Stress Urinary Incontinence
Interventions: fCO2 Laser Therapy Group; Device
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Bacterial Vaginosis
Interventions: Metronidazole, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Bacterial Vaginosis
Interventions: 5% Monolaurin Vaginal Gel, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Iowa City, Iowa • Durham, North Carolina • Cincinnati, Ohio

Conditions: HIV Infections
Interventions: UC-781 carbomer gel, 0.1% and 0.25%; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 21 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 2
States / cities: Atlanta, Georgia • Arlington, Virginia

Conditions: Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions: Health Information Prescription; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Bacterial Vaginosis
Interventions: Tinidazole; Drug
Lead sponsor: Mission Pharmacal; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Vaginosis, Bacterial
Interventions: Not listed
Lead sponsor: American International Biotechnology; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more

Conditions: HIV Infections
Interventions: Tenofovir gel; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Cancer
Interventions: entinostat; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 3
States / cities: Bethesda, Maryland

Search by objective public record fields.

Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women

Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs

Safety Study of Lactobacillus Administered Vaginally to Healthy Women

Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures

Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis

Preventing Recurrent UTI With Vaginal Estrogen

DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)

Trichomonas Vaginalis Repeat Infections Among HIV Negative Women

A Study to Monitor Patients With Primary or Early HIV Infection

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations

Laser Therapy for Treatment of Urogenital Symptoms in Women

Inflammation and Treatment of Bacterial Vaginosis Near Term

Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis

Botswana Study of UC-781 Vaginal Microbicide

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

Treatment of Bacterial Vaginosis With Oral Tinidazole

Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method

Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma